ClinicalTrials.gg
CompletedNCT04504136Updated Sep 30, 2026Results posted

Regulation of Mucosal Healing in Inflammatory Bowel Disease

An interventional study of Serial Biopsy in Inflammatory Bowel Diseases, sponsored by Terrence A Barrett. Completed at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Terrence A Barrett · Not applicable, Interventional, and Basic science

How we know

Updated Sep 30, 2026Now CompletedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.

Enrollment
230th of 327
26 · median 50
Started
2021
with 23 others
No phase
131 of 463
35 open now
Registered
315th of 463
by date

Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 230th largest by enrollment of the 327 interventional ones that give a count, is one of 24 that started in 2021, is one of 131 with no phase, and was the 315th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Inflammatory Bowel Diseases with a site in United States, or all of them as a file.
02

Study summary

The objective of the current study is to compare non-healing colonic ulcers in patients with inflammatory bowel disease (IBD) with iatrogenic colonic ulcers (biopsy sites) in healthy control patients and patients with rheumatoid or psoriatic arthritis. Patients will be biopsied at baseline and again at a follow-up visit in a "biopsy of the biopsy" approach. These biopsies will be used to reveal patterns about gene expression and mitochondrial function during ulcer healing.

Read the detailed description

Induction of mucosal healing in inflammatory bowel disease (IBD) is associated with reduced hospitalizations, surgeries, and reduced cancer risk. However, previous studies have shown that 54-69% of ulcerative colitis (UC) patients fail to heal ulcers after several weeks of treatment, and roughly half do not maintain remission at one year. The single most important factor in preventing severe medical consequences, like colon removal surgery or cancer, is treatment to completely heal the top layer of the intestine as quickly as possible. Healing is a complex process and the dysfunction observed in colitis can only be fully understood by comparison to healing in non-IBD patients.

This is a prospective trial involving three groups of patients: 1) IBD patients with active disease, newly treated with anti-TNF therapy (biologic failure or naïve); 2) non-IBD patients with rheumatoid/psoriatic arthritis who are receiving anti-TNF therapy, and 3) healthy control patients. Biopsies will be collected at baseline during standard of care endoscopy and at a follow-up research endoscopy.

This study will probe mechanisms of ulcer healing by analyzing gene expression patterns and mitochondrial function.

03

Conditions studied

  • Inflammatory Bowel Diseases

Keywords

  • mucosal
  • rheumatoid arthritis
  • psoriatic arthritis
  • ulcer
  • colitis
  • Crohn's
  • mitochondria
  • biopsy
  • wound
  • biologic
  • anti-TNF
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (Group 1):

  • Diagnosed ulcerative colitis or Crohn's disease
  • Biologic failure or naive to biologic treatment
  • Eligible to be treated with anti-TNF therapy

Inclusion Criteria (Group 2):

  • Diagnosed rheumatoid or psoriatic arthritis
  • Receiving anti-TNF antibody therapy at the time of enrollment

Inclusion Criteria (Group 3):

  • Endoscopically unremarkable colonic mucosa
  • Absence of inflammatory bowel disease

Exclusion Criteria:

  • Classified in an anesthesia risk group, ASA Class =4
  • History of bleeding diathesis or coagulopathy
  • Stroke or transient neurological attack with the last 6 months
  • Pregnant
  • Receiving anticoagulants or anti- medications other than low-dose aspirin
  • Receiving therapy or metformin
  • positive
  • Incarceration
  • History of total proctocolectomy
  • History of system chemotherapy within 18 months
  • Uncontrolled intercurrent illness
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Healthy Controls

    Participants in this group will be healthy (not diagnosed with inflammatory bowel disease).

    Procedure: Serial Biopsy

  • Experimental
    Inflammatory Bowel Disease

    Participants in this group will have been diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) and have either failed treatment with biologics or be naive to biologic therapy.

    Procedure: Serial Biopsy

  • Experimental
    Rheumatoid/Psoriatic Arthritis

    Participants in this group will have been diagnosed with rheumatoid (RA) or psoriatic arthritis (PsA) and will be receiving anti-TNF antibody therapy at the time of enrollment.

    Procedure: Serial Biopsy

Interventions

  • ProcedureSerial Biopsy

    During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed. Patients will return for a follow-up colonoscopy 4-35 days later. An additional 16-20 biopsies will be collected in a "biopsy of the biopsy" approach.

06

What researchers measure

Primary outcomes

  1. Change in Relative Ratio of Mitochondrial DNA to Nuclear DNA

    Change in relative ratio of mitochondrial DNA to nuclear DNA in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.

    Time frame: 35 days

  2. Fold Change in Expression Levels of cMyc

    Fold change in expression levels of cMyc (mRNA) will be measured in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.

    Time frame: Baseline and 35 days

  3. Fold Change in Expression Levels of PGC-1 Alpha

    Fold change in expression of PGC-1 alpha (mRNA) will be measured in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.

    Time frame: Baseline and 35 days

  4. Change in Expression Levels of Ki67

    Change in Ki67 alpha (mRNA) expression will be measured by immunohistochemistry in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.

    Time frame: 35 days

  5. Number of Visible Ulcers

    The number of visible ulcers will be assessed during the follow-up endoscopy for healthy patients and rheumatoid/psoriatic arthritis patients only.

    Time frame: 1 day (at follow-up visit)

Secondary outcomes

  1. Change in Full Mayo Score

    Change in Full Mayo Score, a measure of inflammatory bowel disease activity, from baseline to 35 days. The Full Mayo Score ranges from 0-12, with higher scores indicating worse disease activity. The score is calculated by summing the four components of the Mayo Score: stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment.

    Time frame: Baseline and 35 days

  2. Change in Segmental SES-CD Score

    The Simple Endoscopic Score (SES) will be calculated at baseline and follow-up in patients with Crohn's disease (CD) only. The SES-CD score incorporates ulcer size, narrowing, and the area affected by disease or ulceration. Scores range from 0-12; lower scores indicate remission while higher scores indicate severe endoscopic activity.

    Time frame: 35 days

Other outcomes

  1. Fecal Calprotectin Levels

    Levels of fecal calprotectin (ug/g) will be measured from stool samples collected from patients at any time during the study protocol.

    Time frame: 35 days

07

Results

Posted Sep 30, 2026

Participant flow

No participants were able to be enrolled in the Rheumatoid/Psoriatic Arthritis Arm.

Participant flow — Overall Study
MilestoneHealthy ControlsInflammatory Bowel DiseaseRheumatoid/Psoriatic Arthritis
Started15110
Completed10110
Not completed500
Withdrew: Withdrawal by subject300
Withdrew: Lost to follow-up100
Withdrew: No sample collected100

Outcome measures

PrimaryChange in Relative Ratio of Mitochondrial DNA to Nuclear DNA

Change in relative ratio of mitochondrial DNA to nuclear DNA in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.

Time frame:
35 days
Reported as:
Mean · Relative Ratio of mtDNA to nucDNA
Change in Relative Ratio of Mitochondrial DNA to Nuclear DNA
Relative Ratio of mtDNA to nucDNAHealthy ControlsInflammatory Bowel DiseaseRheumatoid/Psoriatic Arthritis
Change in Relative Ratio of Mitochondrial DNA to Nuclear DNA1218.374 ± 148.83394.98 ± 39.22—
PrimaryFold Change in Expression Levels of cMyc

Fold change in expression levels of cMyc (mRNA) will be measured in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.

Time frame:
Baseline and 35 days
Reported as:
Mean · Relative Fold Change
Fold Change in Expression Levels of cMyc
Relative Fold ChangeHealthy ControlsInflammatory Bowel DiseaseRheumatoid/Psoriatic Arthritis
Fold Change in Expression Levels of cMyc2.41 ± 0.241.09 ± 0.225—
PrimaryFold Change in Expression Levels of PGC-1 Alpha

Fold change in expression of PGC-1 alpha (mRNA) will be measured in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.

Time frame:
Baseline and 35 days
Reported as:
Mean · Relative Fold Change
Fold Change in Expression Levels of PGC-1 Alpha
Relative Fold ChangeHealthy ControlsInflammatory Bowel DiseaseRheumatoid/Psoriatic Arthritis
Fold Change in Expression Levels of PGC-1 Alpha0.96 ± 0.020.315 ± 0.05—
PrimaryChange in Expression Levels of Ki67

Change in Ki67 alpha (mRNA) expression will be measured by immunohistochemistry in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.

Time frame:
35 days
Reported as:
Mean · Ki67+Cells/Crypt
Change in Expression Levels of Ki67
Ki67+Cells/CryptHealthy ControlsInflammatory Bowel DiseaseRheumatoid/Psoriatic Arthritis
Change in Expression Levels of Ki6735.8 ± 2.87817 ± 0.997—
PrimaryNumber of Visible Ulcers

The number of visible ulcers will be assessed during the follow-up endoscopy for healthy patients and rheumatoid/psoriatic arthritis patients only.

Time frame:
1 day (at follow-up visit)

No measurements were reported for this outcome.

SecondaryChange in Full Mayo Score

Change in Full Mayo Score, a measure of inflammatory bowel disease activity, from baseline to 35 days. The Full Mayo Score ranges from 0-12, with higher scores indicating worse disease activity. The score is calculated by summing the four components of the Mayo Score: stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment.

Time frame:
Baseline and 35 days
Reported as:
Mean · score on a scale
Change in Full Mayo Score
score on a scaleHealthy ControlsInflammatory Bowel DiseaseRheumatoid/Psoriatic Arthritis
Change in Full Mayo Score—5 ± 0.726—
SecondaryChange in Segmental SES-CD Score

The Simple Endoscopic Score (SES) will be calculated at baseline and follow-up in patients with Crohn's disease (CD) only. The SES-CD score incorporates ulcer size, narrowing, and the area affected by disease or ulceration. Scores range from 0-12; lower scores indicate remission while higher scores indicate severe endoscopic activity.

Time frame:
35 days
Reported as:
Mean · score on a scale
Change in Segmental SES-CD Score
score on a scaleHealthy ControlsInflammatory Bowel DiseaseRheumatoid/Psoriatic Arthritis
Change in Segmental SES-CD Score—8.2 ± 2.28—
Other pre-specifiedFecal Calprotectin Levels

Levels of fecal calprotectin (ug/g) will be measured from stool samples collected from patients at any time during the study protocol.

Time frame:
35 days
Reported as:
Mean · ug/Kg
Fecal Calprotectin Levels
ug/KgHealthy ControlsInflammatory Bowel DiseaseRheumatoid/Psoriatic Arthritis
Fecal Calprotectin Levels151.2 ± 31.931203.57 ± 305.898—

Adverse events

Collected over 30 Days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Controls0/15 (0%)0/15 (0%)0/15 (0%)
Inflammatory Bowel Disease0/11 (0%)0/11 (0%)0/11 (0%)
Rheumatoid/Psoriatic Arthritis———

Baseline characteristics

No participants were able to be enrolled in the Rheumatoid/Psoriatic Arthritis Arm.

Age, Continuous
Age, Continuous(years)Healthy ControlsInflammatory Bowel DiseaseRheumatoid/Psoriatic ArthritisTotal
Mean52.44 ± 13.39836.7 ± 6.815—44.57 ± 11.13
Sex: Female, Male
Sex: Female, Male(Participants)Healthy ControlsInflammatory Bowel DiseaseRheumatoid/Psoriatic ArthritisTotal
Female85—13
Male76—13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Healthy ControlsInflammatory Bowel DiseaseRheumatoid/Psoriatic ArthritisTotal
Hispanic or Latino01—1
Not Hispanic or Latino1510—25
Unknown or Not Reported00—0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Healthy ControlsInflammatory Bowel DiseaseRheumatoid/Psoriatic ArthritisTotal
American Indian or Alaska Native00—0
Asian00—0
Native Hawaiian or Other Pacific Islander00—0
Black or African American21—3
White139—22
More than one race00—0
Unknown or Not Reported01—1
Region of Enrollment
Region of Enrollment(participants)Healthy ControlsInflammatory Bowel DiseaseRheumatoid/Psoriatic ArthritisTotal
United States1511—26
08

Study locations

1 site
  • University of Kentucky
    Lexington, Kentucky 40536, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Aug 2024, 39 months.

Results were first posted in Sep 2026, 2 years 1 month after primary completion.

Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 39 months is above that.

Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jun 2026 → Aug 2024 and completion Jun 2026 → Aug 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2020
First posted
Aug 7, 2020
StartActual
Apr 30, 2021
Primary completionActual
Aug 15, 2024was Jun 2026
CompletionActual
Aug 15, 2024was Jun 2026
Results first posted
Sep 30, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 30, 2026
Results
Results posted
posted Sep 30, 2026
Primary completion
Jun 1, 2026→Aug 15, 2024 (actual)
Sep 30, 2026
Study completion
Jun 1, 2026→Aug 15, 2024 (actual)
Sep 30, 2026
Enrollment
60 (estimated)→26 (actual)
Sep 30, 2026
Primary outcomes
5 edited
What changed in the outcomes
  • EditedChange in mitochondrialRelative Ratio of Mitochondrial DNA copy numberto Nuclear DNATime frame: 35 days
  • EditedFold Change in expression levelsExpression Levels of cMycTime frame: 35 days → Baseline and 35 days
  • EditedFold Change in expression levelsExpression Levels of PGC-1 alphaAlphaTime frame: 35 days → Baseline and 35 days
  • EditedChange in expression levelsExpression Levels of Ki67Time frame: 35 days
  • EditedNumber of visible ulcersVisible UlcersTime frame: 1 day (at follow-up visit)
Sep 30, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedChange in Full Mayo Endoscopic ScoreTime frame: 35 days → Baseline and 35 days
  • Editedother outcomeFecal calprotectin levelsCalprotectin LevelsTime frame: 35 days
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Completed
    Results posted
    Primary completion Jun 1, 2026→Aug 15, 2024 (now actual)
    Study completion Jun 1, 2026→Aug 15, 2024 (now actual)
    Enrollment 60 (estimated)→26 (actual)
    Primary outcomes 5 edited
    What changed in the outcomes
    • EditedChange in mitochondrialRelative Ratio of Mitochondrial DNA copy numberto Nuclear DNATime frame: 35 days
    • EditedFold Change in expression levelsExpression Levels of cMycTime frame: 35 days → Baseline and 35 days
    • EditedFold Change in expression levelsExpression Levels of PGC-1 alphaAlphaTime frame: 35 days → Baseline and 35 days
    • EditedChange in expression levelsExpression Levels of Ki67Time frame: 35 days
    • EditedNumber of visible ulcersVisible UlcersTime frame: 1 day (at follow-up visit)
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedChange in Full Mayo Endoscopic ScoreTime frame: 35 days → Baseline and 35 days
    • Editedother outcomeFecal calprotectin levelsCalprotectin LevelsTime frame: 35 days
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04504136
Lead sponsor
Terrence A Barrett
Responsible party
Terrence A Barrett (Professor, University of Kentucky) — Sponsor-investigator
First posted
Aug 7, 2020
Start date
Apr 30, 2021
Primary completion
Aug 15, 2024
Completion
Aug 15, 2024
Results posted
Sep 30, 2026
Last update
Sep 30, 2026

Study contacts

Terrence Barrett, MD
principal investigator · University of Kentucky

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion